Article Contents ::
- 1 Details About Generic Salt :: Calciton
- 2 Main Medicine Class:: Hormone
- 3 (kal-sih-TOE-nin–salmon) Calcimar, Miacalcin, Osteocalcin, Salmonine Class: Hormone
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Calciton
Main Medicine Class:: Hormone
(kal-sih-TOE-nin–salmon)
Calcimar, Miacalcin, Osteocalcin, Salmonine
Class: Hormone
Drugs Class ::
Action Decreases rate of bone turnover, presumably by regulating bone metabolism (blocking bone resorption). In conjunction with parathyroid hormone endogenous calcitonin regulates serum calcium.
Indications for Drugs ::
Indications Treatment of moderate to severe t’s disease, postmenopausal osteoporosis, hypercalcemia. Nasal spray for treatment of symptomatic t’s disease.
Drug Dose ::
Route/Dosage
t’s Disease
ADULTS: Initial dose: SC/IM 100 IU/day; maintenance: SC/IM 50 IU/day or qod is usually sufficient.
Postmenopausal Osteoporosis
ADULTS: SC/IM 100 IU/day with supplemental calcium and adequate vitamin D intake. Intranasal 200 IU per day, alternating nostrils.
Hypercalcemia
ADULTS: Starting dose: SC/IM 4 IU/kg q 12 hr. Titrate gradually on basis of response to maximum dose of 8 IU/kg q 6 hr.
Contraindication ::
Contraindications Standard considerations.
Drug Precautions ::
Precautions
Pregnancy: Category C. Lactation: Undetermined. Children: Safety and efficacy not established. Allergy: Systemic allergic reactions, including anaphylaxis, may occur. Antibody formation: Circulating antibodies to calcitonin-salmon may occur after 2 to 18 mo of treatment. Treatment may or may not remain effective. Hypocalcemic tetany: May occur with calcitonin, although no cases have been reported. Osteogenic sarcoma: Known to increase in t’s disease.
PATIENT CARE CONSIDERATIONS |
|
Drug Side Effects ::
Adverse Reactions
DERM: Injection site inflammation; flushing of face or hands; pruritus of ear lobes; edema of feet; skin rashes. EENT: Eye pain; salty taste. GI: Nausea with or without vomiting (decreases with continued administration); anorexia; diarrhea; epigastric discomfort; abdominal pain. GU: Nocturia. OTHER: Feverish sensation.
Drug Mode of Action ::
Action Decreases rate of bone turnover, presumably by regulating bone metabolism (blocking bone resorption). In conjunction with parathyroid hormone endogenous calcitonin regulates serum calcium.
Drug Interactions ::
Interactions None well documented.
Drug Assesment ::
Assessment/Interventions
- Obtain patient history, including drug history and any known allergies. Inquire about possible allergy to fish protein.
- Intradermal testing should be considered before first full therapeutic dose is given, to determine hypersensitivity.
- Have epinephrine (1:1000), antihistamines, and resuscitation equipment available in case anaphylaxis occurs.
- Use padded siderails and keep bed in low position if twitching or paresthesia occurs.
- Institute safety precautions to prevent falls.
- During early therapy have parenteral calcium available in case hypocalcemia occurs.
- Monitor serum calcium levels weekly during initial therapy.
- Periodically monitor BUN, serum creatinine, alkaline phosphatase, urinary hydroxyproline excretion (every 24 hr), parathyroid hormone levels, and electrolytes.
- Observe for signs of anaphylaxis, especially early in treatment. Notify physician immediately if any of these signs occur.
- Assess patient for signs of hypocalcemia: Tachycardia, paresthesia, muscle cramps, laryngospasm, twitching, colic, Chvostek’s or Trousseau’s sign. Notify physician if any of these signs occur.
|
Drug Storage/Management ::
Administration/Storage
- Administer by SC or IM injection. For doses > 2 ml, use IM site.
- Rotate injection sites to prevent skin irritation.
- Give medication at bedtime to reduce nausea and flushing.
- Keep medication under refrigeration.
Drug Notes ::
Patient/Family Education
- Teach patient aseptic injection technique.
- Instruct patient to rotate injection sites.
- Explain comfort measures to be used for injection sites.
- Emphasize importance of maintaining adequate intake of vitamin D.
- Explain that nausea is a common side effect, usually occurring 30 min after injection, and will lessen during course of therapy.
- Tell patient that other side effects include anorexia, vomiting, diarrhea, and flushing of face, ears, hands, and feet.
- If patient is taking medication for osteoporosis, explain need for maintaining proper levels of total calcium (1.5 g/day) and vitamin D.
- Remind patient that follow-up office visits and lab tests are necessary.
- Caution patient to follow low-calcium diet if ordered and to avoid high-calcium foods such as bok choy, broccoli, canned salmon/sardines, clams, cream soups, milk and dairy products, blackstrap molasses, oysters, spinach, tofu.
- Instruct patient not to take otc medications without consulting physician.